Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Cytosorbents Corporation (CTSO) had Revenue of $9.62M for the most recently reported fiscal quarter, ending 2025-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-06-30

Income Statement Financials
Revenue	$9.62M
Net Income	$1.95M
Cost of Goods Sold	$2.80M
Gross Profit	$6.81M
Operating Expenses	$13.23M
Operating Income	$-3.62M
Non-Operating Income/Expense	$5.56M
Pre-Tax Income	$1.95M
Normalized Pre-Tax Income	$1.95M
Income after Taxes	$1.95M
Income from Continuous Operations	$1.95M
Consolidated Net Income/Loss	$1.95M
Normalized Income after Taxes	$1.95M
EBIT	$-3.62M
EBITDA	$-2.98M
Weighted-Average Shares Outstanding (Basic)	62.61M
Weighted-Average Shares Outstanding (Diluted)	67.17M
Earnings per Share (EPS) (Basic)	$0.03
Earnings per Share (EPS) (Diluted)	$0.03
Balance Sheet Financials
Current Assets	$22.99M
Property, Plant, and Equipment	$8.47M
Long-Term Assets	$25.00M
Total Assets	$47.99M
Current Liabilities	$9.84M
Long-Term Debt	$14.38M
Long-Term Liabilities	$26.56M
Total Liabilities	$36.40M
Common Equity	$11.59M
Tangible Shareholders Equity	$11.59M
Shareholders Equity	$11.59M
Common Shares Outstanding	62.61M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-4.97M
Cash Flow from Investing Activities	$-0.18M
Cash Flow from Financial Activities	$6.83M
Beginning Cash	$9.76M
End Cash	$11.73M
Increase/Decrease in Cash	$1.96M
Stock-Based Compensation	$1.39M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.34
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.55
Debt to Equity Ratio	1.24
Gross Margin	70.85%
Operating Margin	-37.59%
EBIT Margin	-37.59%
EBITDA Margin	--
Pre-Tax Profit Margin	20.25%
Profit Margin	20.25%
Free Cash Flow	$-5.01M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.20
Inventory Turnover	0.76
Receiveable Turnover	1.24
Days Sales in Receivables	72.46
Return on Equity	16.80%
Return on Tangible Equity	16.80%
Return on Assets	4.06%
Return on Investments	7.50%
Book Value Per Share	$0.19
Free Cash Flow per Share	$-0.07
Operating Cash Flow per Share	$-0.07

Data from Zacks Investment Research, Inc.